Back to Search
Start Over
IL-17A and TNF synergistically drive expression of proinflammatory mediators in synovial fibroblasts via IκBζ-dependent induction of ELF3.
- Source :
-
Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2023 Feb 01; Vol. 62 (2), pp. 872-885. - Publication Year :
- 2023
-
Abstract
- Objective: IL-17A and TNF act in synergy to induce proinflammatory mediators in synovial fibroblasts thus contributing to diseases associated with chronic arthritis. Many of these factors are regulated by transcription factor E74-like factor-3 (ELF3). Therefore, we sought to investigate ELF3 as a downstream target of IL-17A and TNF signalling and to characterize its role in the molecular mechanism of synergy between IL-17A and TNF.<br />Methods: Regulation of ELF3 expression by IL-17A and TNF was studied in synovial fibroblasts of RA and OA patients and RA synovial explants. Signalling leading to ELF3 mRNA induction and the impact of ELF3 on the response to IL-17A and TNF were studied using siRNA, transient overexpression and signalling inhibitors in synovial fibroblasts and HEK293 cells.<br />Results: ELF3 was marginally affected by IL-17A or TNF alone, but their combination resulted in high and sustained expression. ELF3 expression was regulated by the nuclear factor-κB (NF-κB) pathway and CCAAT/enhancer-binding protein β (C/EBPβ), but its induction required synthesis of the NF-κB co-factor IκB (inhibitor of NF-κB) ζ. siRNA-mediated depletion of ELF3 attenuated the induction of cytokines and matrix metalloproteinases by the combination of IL-17A and TNF. Overexpression of ELF3 or IκBζ showed synergistic effect with TNF in upregulating expression of chemokine (C-C motif) ligand 8 (CCL8), and depletion of ELF3 abrogated CCL8 mRNA induction by the combination of IκBζ overexpression and TNF.<br />Conclusion: Altogether, our results establish ELF3 as an important mediator of the synergistic effect of IL-17A and TNF in synovial fibroblasts. The findings provide novel information of the pathogenic mechanisms of IL-17A in chronic arthritis and implicate ELF3 as a potential therapeutic target.<br /> (© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology.)
- Subjects :
- Humans
Interleukin-17 pharmacology
Interleukin-17 metabolism
HEK293 Cells
RNA, Small Interfering pharmacology
RNA, Messenger metabolism
Fibroblasts metabolism
Synovial Membrane metabolism
Cells, Cultured
Tumor Necrosis Factor-alpha pharmacology
Tumor Necrosis Factor-alpha metabolism
DNA-Binding Proteins genetics
DNA-Binding Proteins metabolism
Transcription Factors metabolism
Proto-Oncogene Proteins c-ets metabolism
Proto-Oncogene Proteins c-ets pharmacology
NF-kappa B
Arthritis metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1462-0332
- Volume :
- 62
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Rheumatology (Oxford, England)
- Publication Type :
- Academic Journal
- Accession number :
- 35792833
- Full Text :
- https://doi.org/10.1093/rheumatology/keac385